Blood test to monitor advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study looks at whether a simple blood test can help track advanced colorectal cancer over time. It may help doctors see how well treatment is working and when the disease might progress, without needing repeated scans or biopsies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer that has spread (metastatic) or cannot be removed with surgery.
- You are either about to start your first treatment for metastatic cancer, are currently receiving it, or have already completed it (depending on the part of the study).
- For some participants, stored blood or tissue samples from earlier must be available for testing.
- If you are joining the part for new patients, you must not have had treatment for metastatic cancer before, but earlier chemotherapy or radiation given as an extra precaution (adjuvant or neoadjuvant) is okay if it finished at least 6 months ago.
- You must be willing and able to give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA methylation) can help monitor how well treatment is working in people with colorectal cancer that has spread. If you are getting radiation and chemotherapy (with or without an immunotherapy drug), this trial may help your doctor see if the treatment is working sooner.
This study looks at whether a simple blood test can help guide the care of people being evaluated for colorectal cancer. It may support earlier or clearer decision-making alongside existing screening or colonoscopy results.
This study looks at a blood “DNA” test to see if it can help monitor colorectal cancer after surgery. It may benefit you by improving how doctors track cancer during routine follow-up visits.
This study measures “minimal residual disease,” meaning tiny amounts of cancer that may remain after surgery, using blood samples. It may help doctors better detect who is at higher risk of cancer coming back and guide follow-up care.
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.